文献速递认知障碍与痴呆

IDH1/2突变低级别胶质瘤患者临床、肿瘤及治疗特征与癫痫控制的相关性

Association of Clinical, Tumor, and Treatment Characteristics With Seizure Control in Patients With IDH1/2-Mutant Lower-Grade Glioma.
PubMed 文献 · Neurology · 2024-04-29

该回顾性研究纳入150例IDH1/2突变低级别胶质瘤伴癫痫患者,分析肿瘤/患者特征及手术与辅助治疗对癫痫控制的影响。结果显示3级组织学与术后2个月、辅助治疗后6个月及复发治疗后6个月的无癫痫发作正相关,术后及辅助治疗后无癫痫发作与更长无进展生存期相关。

要点

  • 3级组织学与术后2个月、辅助治疗后6个月及复发治疗后6个月的无癫痫发作正相关。
  • 辅助放疗在单变量分析中减少复发时癫痫发作(OR 0.14)。
  • 术后及辅助治疗后无癫痫发作与更长无进展生存期相关(65 vs 48个月)。

核心结论

  • 3级组织学与整个疾病轨迹中更好的癫痫控制相关,术后及辅助治疗后无癫痫发作与更长无进展生存期相关, regardless of tumor grade。

研究设计与样本

  • 回顾性纳入150例IDH1/2突变低级别胶质瘤患者,来自都灵和米兰大学神经外科,在都灵神经肿瘤科治疗,纳入标准为2021 WHO分类诊断且以癫痫发作为表现,排除CDKN2A/B纯合缺失、MRI上明显/环形强化及小组织活检。

主要发现

  • IDH突变/1p19q共缺失2级和3级少突胶质瘤分别为77例(51%)和31例(21%),IDH突变2级和3级星形细胞瘤分别为30例(20%)和12例(8%)。
  • 全切除68例(45%),75例(50%)接受辅助治疗,另75例MRI观察。
  • 辅助治疗后6个月,29例中28例(96.5%)癫痫减少,28例中5例(18%)无癫痫发作。
  • 复发时124例中66例(53%)有癫痫发作;二线治疗后6个月,66例中60例(91%)癫痫减少,11例(17%)无癫痫发作。
  • 多变量分析中,3级组织学与术后2个月无癫痫发作(OR 3.5,1.4-8.9,p=0.008)、辅助治疗后6个月(OR 9.0,1.5-54.9,p=0.017)及复发治疗后6个月(OR 4.9,1.5-16.5,p=0.009)正相关。

关键数值与推荐

  • 3级组织学与术后2个月无癫痫发作正相关(OR 3.5,1.4-8.9,p=0.008)。
  • 3级组织学与辅助治疗后6个月无癫痫发作正相关(OR 9.0,1.5-54.9,p=0.017)。
  • 3级组织学与复发治疗后6个月无癫痫发作正相关(OR 4.9,1.5-16.5,p=0.009)。
  • 辅助放疗与复发时癫痫发作减少相关(OR 0.14,0.03-0.7,p=0.020,单变量分析)。

临床怎么用

  • 作者认为这些结果可作为外部对照臂用于评估抗肿瘤药物对IDH突变低级别胶质瘤患者癫痫疗效的临床试验。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Patients with IDH1/2-mutant lower-grade glioma have a high frequency of seizures. We aimed to investigate the correlations between seizures and tumor/patient characteristics and the impact of surgery and adjuvant treatments (AT) on seizure control along the disease trajectory. METHODS: We retrospectively included patients with IDH1/2-mutant lower-grade glioma who underwent surgery at the neurosurgery divisions of the University of Turin and Milan and were treated at the Division of Neuro-Oncology of Turin. Inclusion criteria were a diagnosis according to the 2021 WHO Classification and presentation with seizures; exclusion criteria were presence of CDKN2A/B homozygous deletion, intense/ring contrast enhancement on MRI at presentation, and small tissue biopsy. We evaluated seizure freedom for 2 months after surgery, 6 months from starting observation or AT, at recurrence, and for 6 months after treatments of recurrence. RESULTS: We included 150 patients. There were 77 (51%) and 31 (21%) patients with IDH-mutant/1p19q-codeleted grade 2 and 3 oligodendroglioma and 30 (20%) and 12 (8%) with IDH-mutant grade 2 and 3 astrocytoma, respectively. Total resection was accomplished in 68 (45%). Seventy-five patients (50%) received AT while the remaining 75 were observed with MRI. After 6 months after AT, 28 of 29 patients (96.5%) displayed seizure reduction, 5 of 28 (18%) being seizure-free. 66 of 124 patients (53%) had seizures at recurrence. After 6 months after second-line treatments, 60 of 66 patients (91%) had seizure reduction, 11 (17%) being seizure-free. In multivariable analyses, grade 3 histology positively correlated with seizure freedom at 2 months after surgery (OR 3.5, 1.4-8.9, p = 0.008), 6 months after AT (OR 9.0, 1.5-54.9, p = 0.017), and 6 months after treatment of recurrence (OR 4.9, 1.5-16.5, p = 0.009). Adjuvant radiotherapy reduced seizures at recurrence in a univariate analysis (OR 0.14, 0.03-0.7, p = 0.020). Patients with seizure freedom after surgery and AT displayed longer progression-free survival (PFS) (65, 24.5-105, vs 48 months, 32-63.5, p = 0.037). DISCUSSION: This study analyzed seizure control in patients with IDH1/2-mutant lower-grade glioma across multiple time points. Grade 3 correlated with better seizure control throughout the entire disease trajectory, and seizure freedom after surgery and AT correlated with a longer PFS regardless of tumor grade. These results could serve as an external control arm in clinical trials evaluating the efficacy on seizures of antitumor agents in patients with IDH-mutant lower-grade glioma.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Bruno F, Pellerino A, Conti Nibali M, et al. Association of Clinical, Tumor, and Treatment Characteristics With Seizure Control in Patients With IDH1/2-Mutant Lower-Grade Glioma. Neurology. 2024. PMID: 38684041. doi:10.1212/WNL.0000000000209352

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。